Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

MLA

Chiricozzi, Andrea, et al. “Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.” Dermatitis, vol. 33, no. 3, May 2022, pp. e25–29. EBSCOhost, https://doi.org/10.1097/DER.0000000000000814.

APA

Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., … Peris, K. (2022). Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy. Dermatitis, 33(3), e25–e29. https://doi.org/10.1097/DER.0000000000000814

Chicago

Chiricozzi, Andrea, Lucia Di Nardo, Marina Talamonti, Marco Galluzzo, Clara De Simone, Gabriella Fabbrocini, Angelo Valerio Marzano, et al. 2022. “Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.” Dermatitis 33 (3): e25–29. doi:10.1097/DER.0000000000000814.